(C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes

Size: px
Start display at page:

Download "(C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes"

Transcription

1 (A) (B) (C) Fig 5.1 Classical non alcoholic steatohepatitis (NASH). (A) Steatosis, hepatocyte ballooning, and inflammation (the trio of changes representing the minimal histological criteria of steatohepatitis) are evident in the centrilobular region (C). (B) Hepatocyte ballooning and intracellular Mallory Denk bodies (arrow) are shown at high magnification. (C) The characteristic pericellular/perisinusoidal chicken wire pattern of fibrosis surrounding centrilobular hepatocytes is seen on this trichrome stain (A and B, hematoxylin and eosin stain; C: Masson trichrome stain). Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease, First Edition. Edited by Roger Williams and Simon D. Taylor-Robinson John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd.

2 (A) (B) (C) Fig 5.2 Cryptogenic cirrhosis due to NAFLD. (A) Cirrhosis without fat is seen at low magnification. Portal tracts and fibrous septa contain mild to moderate chronic inflammatory cell infiltrates, rendering a superficial resemblance to chronic hepatitis. However, careful examination of the hepatocytes located at the periphery of the nodules (arrow) allows recognition of remaining NASH features (seen at high power in panel B). (B) High magnification of the parenchyma near the arrow in panel A. Hepatocytes are variably ballooned and there is robust Mallory Denk body formation (arrows). (C): Occasional periportal/periseptal hepatocytes show glycogenated nuclei (arrows) (A, B, and C: hematoxylin and eosin stain).

3 Injury and death Dying hepatocytes Hepatocytes Release Hedgehog ligands Quiescent hepatic stellate cell Cholangiocytes/ ductular progenitors Release Hedgehog ligands Immune cells Release Hedgehog ligands Activated hepatic stellate cell/myofibroblast Fig 8.1 Link between cell death and fibrogenic liver repair. Liver cell injury or death from lipotoxicity, oxidative stress and immune imbalance leads to the release of signalling factors (such as Hedgehog ligands), which promote the proliferation of ductular progenitors and liver pericytes (hepatic stellate cells) as part of the repair response. Stimulated hepatic stellate cells transition into collagenproducing myofibroblasts, and ductular progenitor cells secrete high levels of cytokines and growth factors that recruit immune cells into the liver. In turn, recruited immune cells secrete even more cytokines and growth factors that perpetuate the inflammatory and fibrogenic response. Ductular progenitors may also undergo direct differentiation into scar producing myofibroblasts.

4 (A) (B) (C) (D) Fig 9.1 Non-alcoholic fatty liver disease. Examples of the zone 3 and zone 1 injury patterns. (A) Typical steatohepatitis with perivenular inflammation and ballooning (arrows). (B) Masson trichrome stain from the same case showing delicate zone 3 perisinusoidal fibrosis. (C) Zone 1 borderline pattern with periportal steatosis and portal inflammation. No injury is seen around the terminal hepatic venule (arrowhead). (D) Masson trichrome stain from the same case showing periportal fibrosis but no perivenular fibrosis (arrowhead).

5 (A) (B) (C) (D) Fig 9.2 Alcoholic liver disease. (A) This is an example of alcoholic steatohepatitis. Steatosis is apparent along the right side; marked ballooning and Mallory Denk bodies are noted in hepatocytes along the left. Satellitosis is also seen as well as ductular reaction. (B D) These figures are from a patient who presented with signs and symptoms of venous outflow obstruction. (B) In this example of several alcoholic hepatitis, there is very little steatosis, and one can appreciate near obliteration of all vascular (terminal hepatic venule and portal tract) structures. The primary component of the cellular infiltrate is neutrophils. With close inspection, Mallory Denk bodies can be seen, as well as bile stained hepatocytes. This is an example of sclerosing hyaline necrosis and would not be seen in NAFLD/ NASH. (C) A low power trichrome stain shows obliterative fibrosis of a centrilobular region; this extent and type of fibrotic response are not described in NAFLD/NASH. (D) The high power view of the Masson trichrome highlights the remnant of a terminal hepatic venule centrally and dense sinusoidal fibrosis in the lobules. Capillarization to this extent in alcoholic liver disease results in portal hypertension without the classic histologic features of cirrhosis.

6 Adipose Weight gain Adipose tissue expansion Macrophage infiltration TNF-α IL-6 Insulin resistance Lipolysis FFA generation Leptin Adiponectin Adipose Liver Pancreas Insulin sensitivity Pancreatic beta cell loss Hepatic insulin sensitivity Inflammation SREBP-1-mediated lipogenesis β-oxidation of fatty acids Fig 10.1 Weight gain leads to adipose tissue expansion and inflammation, which results in a proinflammatory state. These adipokines worsen adipose tissue and hepatic and systemic insulin resistance. The deterioration in insulin sensitivity leads to pancreatic β cell loss, de novo lipogenesis, and hepatic steatosis.

7 FFA pool TG synthesis VLDL secretion Hepatic insulin sensitivity Simple steatosis Intestinal microbiome Kupffer cell activation hscrp LPS Steatohepatitis Polysaccharide SCFA SCFA SCFA SCFA LPS LPS LPS LPS Constituent low-grade endotoxemia LPS LPS (Metabolic endotoxemia) Adipose tissue Increased intestinal permeability Expansion inflammation decreased insulin sensitivity Small intestinal bacterial overgrowth Disruption of tight junctions Intestinal lumen Intestinal epithelium Portal vein Fig 10.2 NAFLD is associated with an increase in small intestinal bacterial overgrowth (SIBO). The intestinal microbiome breaks down polysaccharides into short chain fatty acids (SCFAs), and increased bacterial productions (i.e., LPS) are then readily absorbed into the portal circulation. These by products of digestion and intestinal microbiome subsequently influence insulin resistance and hepatic triglyceride synthesis and impair hepatic triglyceride synthesis leading to hepatic steatosis.

8 Gut lumen Dietary intake Choline Choline Phosphatidylcholine Availability Choline VLDL secretion Intrahepatic TG accumulation Microbiome Metabolism Methylamine Hepatotoxicity Fig 10.3 The gut microbiota catalyzes the conversion of dietary choline into methylamines, which enter the portal circulation and promote hepatocellular injury. The conversion of choline to methylamines also reduces the bioavailability of choline, leading to phosphatidylcholine deficiency, which impairs VLDL secretion and promotes steatosis. Fig 16.7 The hepatic fat fraction (HFF) map calculated using water and fat separation GRE images. The color scale on the side indicates the percent HFF

9 Fig 16.8 Proton density hepatic fat fraction (PD HFF) map of the entire liver. The color scale on the side indicates the percent HFF. 0 Freq diff = Hz: or ppm Fig Single voxel proton MR spectroscopy of a fatty liver at 1.5 T. Note the small red voxel placed in the right lobe of the liver and the water (arrowhead) and dominant fat (methylene) (arrow) peaks in the sampled parenchyma.

10 (A) (B) Fig 17.1 (A) Liver biopsy section with H&E staining at 200 magnification, showing simple severe steatosis. (B) Liver biopsy section with H&E staining at 400 magnification, showing non alcoholic steatohepatitis with ballooning, Mallory s hyaline, glycogenated nuclei, portal and lobular inflammation (Source: Courtesy of Dr Eve Fryer, Oxford University Hospitals NHS Trust).

11 Pulmonary Hypoventilation Obstructive sleep apnoea Asthma Dermatological Hirsutism Sweating Psoriasis Gastrointestinal Gall stones Non-Alcoholic fatty liver Colon cancer Gastro oesophageal reflux Oesophageal cancer Periodontal disease Gynaecological/obstetric Oligomenorrhea Infertility Cancer of uterus, breast, cervix Pregnancy morbidity CNS Intracranial hypertension Migraine/headache Stroke Psychological/Psychiatric Dementia Cardiovascular Hypertension Ischaemic heart disease Heart failure Thromboembolism Metabolic Diabetes Dyslipaemia Hyperinsulinaemia Musculo skeletal Osteoarthritis Gout Andrology Hypogonadism Prostate cancer Fig 19.1 The spectrum of disease linked to overweight and obesity ( Source: Science Photo Library C007/2245 (Obese woman, MRI scan). Reproduced with permission from Science Photo Library).

12 Fig 22.1 Gastric bypass. Fig 22.2 Sleeve gastrectomy. Me DNA methylation Lifestyles Diseases Nutrition Me Me Methylation pattern Me Histone modification Lifestyles Diseases Nutrition Methylation pattern Others Chromatin remodeling microrna Fig 26.1 The main epigenetic reactions are the methylation of CpG sites and the modifications on amino acidic tails of histones such as by methylation, acetylation or phosphorylation. These reactions could be influenced by factors such as lifestyles, diseases and diet, and the final conformation of DNA could facilitate joining of the transcription factors (Source: (left) Qiu [40], reproduced with permission of Nature Publishing Group and (right) Cordero et al. [41]).

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic

More information

Nottingham Patterns of liver fibrosis and their clinical significance

Nottingham Patterns of liver fibrosis and their clinical significance Nottingham 2006 Patterns of liver fibrosis and their clinical significance Alastair D Burt Professor of Pathology and Dean of Clinical Medicine University of Newcastle upon Tyne Collapse of reticulin

More information

Steatotic liver disease

Steatotic liver disease Steatotic liver disease Fatty liver disease Prof. Dr. ANNE HOORENS Non-Neoplastic Liver Pathology December 8th 2018 Working Group of Digestive Pathology Belgian Society of Pathology OUTLINE NAFLD = Non-Alcoholic

More information

Improving Access to Quality Medical Care Webinar Series

Improving Access to Quality Medical Care Webinar Series Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX

More information

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem

More information

Liver Pathology in the 0bese

Liver Pathology in the 0bese Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Abetalipoproteinemia NASH and, 537 Acquired errors of metabolism NASH and, 536 537 Amiodarone steatohepatitis due to, 527 Anticonvulsant mood

More information

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle

More information

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology Nonalcoholic steatohepatitis and Fatty Liver Disease Liver manifestations of the obesity epidemic Changes

More information

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015 1 A Brief Introduction to the Liver Sessions 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology Sarajevo, 6 th -7 th November 2015 Stefan Hübscher, Institute of Immunology & Immunotherapy,

More information

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 I HAVE NOTHING TO DISCLOSE Linda Ferrell PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES Linda Ferrell, MD, UCSF THE PROBLEM

More information

Chapter 18 Liver and Gallbladder

Chapter 18 Liver and Gallbladder Chapter 18 Liver and Gallbladder 解剖學科徐淑媛 本堂重點 1. Liver : functions & histology 2. Gallbladder Physiology Liver Produce circulating plasma proteins Vitamin Iron Degradation Metabolism Bile manufacture (exocrine)

More information

Challenges in the Diagnosis of Steatohepatitis

Challenges in the Diagnosis of Steatohepatitis The Bugaboos of Fatty Liver Disease: Ballooning and Fibrosis Hans Popper Hepatopathology Society Companion Meeting San Antonio, Tx March, 2017 David Kleiner, M.D., Ph.D. NCI/Laboratory of Pathology Challenges

More information

Paneth Cells. Road Map to the Finish. No Review this Friday. Today 11/29 Finish digestion/accessory organs. Wednesday 12/1 Immune System I

Paneth Cells. Road Map to the Finish. No Review this Friday. Today 11/29 Finish digestion/accessory organs. Wednesday 12/1 Immune System I Road Map to the Finish No Review this Friday Today 11/29 Finish digestion/accessory organs Wednesday 12/1 Immune System I Paneth Cells - base of intestinal glands -! large -! intense acidophilic granules

More information

Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis

Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis Naoki Tanaka 1, Akira Horiuchi 2, Takahide Yokoyama 3, Shigeyuki Kawa 1, and Kendo Kiyosawa 1 1 Department of Gastroenterology,

More information

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts. Many of the histologic images and the tables are from MacSween s Pathology of the Liver (5 th Edition). Other images were used from an online source called PathPedia.com. A few images from other sources

More information

British Liver Transplant Group Pathology meeting September Leeds cases

British Liver Transplant Group Pathology meeting September Leeds cases British Liver Transplant Group Pathology meeting September 2014 Leeds cases Leeds Case 1 Male 61 years Liver transplant for HCV cirrhosis with HCC in January 2014. Now raised ALT and bilirubin,? acute

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty

More information

HISTOPL4THOLOG1CAL STUDY OF LIVER

HISTOPL4THOLOG1CAL STUDY OF LIVER HISTOPL4THOLOG1CAL STUDY OF LIVER 6.1 Inti-oduction The structural and functional organization of the liver has been described by hepatic lobule and hepatic acinus models, respectively (Jarvelainen, 2000).

More information

WEIGHT LOSS SURGERY A Primer on Current Options and Outcomes. Caitlin A. Halbert DO, MS, FACS, FASMBS April 5, 2018

WEIGHT LOSS SURGERY A Primer on Current Options and Outcomes. Caitlin A. Halbert DO, MS, FACS, FASMBS April 5, 2018 WEIGHT LOSS SURGERY A Primer on Current Options and Outcomes Caitlin A. Halbert DO, MS, FACS, FASMBS April 5, 2018 A Little Bit About Me Bariatric Surgical Services Reflux Surgery General Surgery Overview

More information

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty

More information

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H. U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,

More information

NASH Bench to Bedside

NASH Bench to Bedside NASH Bench to Bedside October 2006 Anna Mae Diehl, M.D. Gastroenterology Division Duke University NonAlcoholic Fatty Liver Disease Common ~1/4-1/3 1/3 US adults Outcome highly variable Course indolent

More information

Supplementary Figure S1. Effect of Glucose on Energy Balance in WT and KHK A/C KO

Supplementary Figure S1. Effect of Glucose on Energy Balance in WT and KHK A/C KO Supplementary Figure S1. Effect of Glucose on Energy Balance in WT and KHK A/C KO Mice. WT mice and KHK-A/C KO mice were provided drinking water containing 10% glucose or tap water with normal chow ad

More information

Case Presentation. Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010

Case Presentation. Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010 Case Presentation Mary Beth Patterson, MD Harbor-UCLA Medical Center February 23, 2010 Case HPI: 4 yo female with PMHx of obesity sent to ED from clinic with BS of 353. Pt. has had polyuria for the past

More information

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes

More information

Digestive system L 4. Lecturer Dr. Firdous M. Jaafar Department of Anatomy/Histology section

Digestive system L 4. Lecturer Dr. Firdous M. Jaafar Department of Anatomy/Histology section Digestive system L 4 Lecturer Dr. Firdous M. Jaafar Department of Anatomy/Histology section objectives 1-Describe the structure of liver. 2-Define liver lobule, and identify its zones. 3-Define portal

More information

Non-Alcoholic Fatty Liver Disease An Update

Non-Alcoholic Fatty Liver Disease An Update Non-Alcoholic Fatty Liver Disease An Update Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth Hospital, Birmingham First described in 1980

More information

Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes. Carla Venturi Monteagudo MD, PhD

Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes. Carla Venturi Monteagudo MD, PhD Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes Carla Venturi Monteagudo MD, PhD THE NORMAL LIVER ARCHITECTURE Parenchymal Cells -Hepatocytes -Cholangiocytes

More information

Access to Proven Therapies

Access to Proven Therapies Access to Proven Therapies Obesity is a life-threatening disease affecting 34% of adults in the U.S. Between 2000 and 2005, obesity increased by 24%, morbid obesity by 50%, and super obesity by 75%. 18%

More information

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba University of Groningen Non-alcoholic fatty liver disease Sheedfar, Fareeba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check

More information

Case n 1 ( B 92 / 4208 ) Case n 2 ( B 00 / 8249 ) Case n 3 ( B 98 / 8352 )

Case n 1 ( B 92 / 4208 ) Case n 2 ( B 00 / 8249 ) Case n 3 ( B 98 / 8352 ) Slide Seminar Case n 1 ( B 92 / 4208 ) 16 month-old girl. HBV serology +. Clinic in favour of chronic hepatitis. 4 portal triads! classification limited Viral B chronic hepatitis Mild activity (Fig. 1

More information

HOW THE MICROBIOME AFFECTS OUR HEALTH

HOW THE MICROBIOME AFFECTS OUR HEALTH HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins

More information

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi

More information

Week 3 The Pancreas: Pancreatic ph buffering:

Week 3 The Pancreas: Pancreatic ph buffering: Week 3 The Pancreas: A gland with both endocrine (secretion of substances into the bloodstream) & exocrine (secretion of substances to the outside of the body or another surface within the body) functions

More information

CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT. Background and Significance

CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT. Background and Significance CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT Background and Significance The metabolic syndrome (MetS) is defined in an individual who has

More information

Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis

Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis Annu. Rev. Pathol. Mech. Dis. 2010. 5:145 71 First published online as a Review in Advance on September 30, 2009 The Annual Review of Pathology: Mechanisms of Disease is online at pathmechdis.annualreviews.org

More information

METABOLIC SYNDROME AND HCV: FROM HCV

METABOLIC SYNDROME AND HCV: FROM HCV METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,

More information

NONALCOHOLIC FATTY LIVER DISEASE

NONALCOHOLIC FATTY LIVER DISEASE NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis

More information

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012 NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat

More information

LIVER PHYSIOLOGY AND DISEASE

LIVER PHYSIOLOGY AND DISEASE GASTROENTEROLOGY C opy ri~ht 1972 by The Williams & Wilkins Co. Vol. 62. No.3 Printed in U.S.A. LIVER PHYSIOLOGY AND DISEASE SPLENOMEGALY IN UNCOMPLICATED BILIARY TRACT AND PANCREATIC DISEASE PETER B.

More information

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis

More information

ACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust

ACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust ACP-BSG meeting 10.12.09 The liver in systemic inflammatory disorders Dr Adrian C Bateman Southampton University Hospitals NHS Trust Wide range of diseases General inflammatory disorders Connective tissue

More information

Clinical Staging for Obesity. Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta

Clinical Staging for Obesity. Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta Clinical Staging for Obesity Raj Padwal Clinical Pharmacology and General Internal Medicine University of Alberta Disclosures Funding: CIHR, Heart and Stroke Foundation of Canada, University Hospital Foundation.

More information

Conflicts of Interest in the last 12 months

Conflicts of Interest in the last 12 months STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last

More information

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis

More information

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways Department of Gastroenterology, Endocrinology & Metabolism Medical University Innsbruck Herbert Tilg Nothing to disclose Fig.

More information

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006 Vt-2006 The pathology of the liver, bile ducts and pancreas Richard Palmqvist Docent, ST-läkare, Klin Pat Lab, Labcentrum The lecture in summary Introduction, histology & physiology in brief General phenomenon

More information

Not over when the surgery is done: surgical complications of obesity

Not over when the surgery is done: surgical complications of obesity Not over when the surgery is done: surgical complications of obesity Gianluca Bonanomi, MD, FRCS Consultant Surgeon and Honorary Senior Lecturer Chelsea and Westminster Hospital London The Society for

More information

Histopathology: Cell necrosis and cytoplasmic accumulations

Histopathology: Cell necrosis and cytoplasmic accumulations Histopathology: Cell necrosis and cytoplasmic accumulations These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you

More information

Pathology of Fatty Liver Disease

Pathology of Fatty Liver Disease 1 Fatty Liver Disease - Causes Pathology of Fatty Liver Disease Role of Liver Biopsy in (Non-Alcoholic) Fatty Liver Disease Stefan Hübscher, Institute of Immunology & Immunotherapy, University of Birmingham

More information

Fat Metabolism, Insulin and MTHFR

Fat Metabolism, Insulin and MTHFR Fat Metabolism, Insulin and MTHFR BCAA, SAMe and ACAT Carolyn Ledowsky Overview of This Presentation 1. Fat Metabolism and MTHFR 2. SAMe and Fat Metabolism 3. Acetyl Co A and Fat Metabolism 4. How to Maintain

More information

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion

More information

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D.

Effective Interventions in the Clinical Setting: Engaging and Empowering Patients. Michael J. Bloch, M.D. Doina Kulick, M.D. Effective Interventions in the Clinical Setting: Engaging and Empowering Patients Michael J. Bloch, M.D. Doina Kulick, M.D. UNIVERSITY OF NEVADA SCHOOL of MEDICINE Sept. 8, 2011 Reality check: What could

More information

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary

More information

Obesity and Cancer Survivorship. Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona

Obesity and Cancer Survivorship. Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona Obesity and Cancer Survivorship Cynthia Thomson, PhD, RD Professor-Mel & Enid Zuckerman College of Public Health University of Arizona Objectives Describe the relationship between obesity, weight gain

More information

Lipids digestion and absorption, Biochemistry II

Lipids digestion and absorption, Biochemistry II Lipids digestion and absorption, blood plasma lipids, lipoproteins Biochemistry II Lecture 1 2008 (J.S.) Triacylglycerols (as well as free fatty acids and both free and esterified cholesterol) are very

More information

Improving the Lives of Patients with Liver Diseases

Improving the Lives of Patients with Liver Diseases Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and

More information

MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST

MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST HUMAN MICROBIOM 10 Billion bacterias are building a 1,5 2 kg heavy human microbiom It is located mainly in the human gut There is a intestinal controlled

More information

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined

More information

Prelab #4 BLOOD; BONE MARROW; RESPIRATORY; INTEGUEMENT Page 1

Prelab #4 BLOOD; BONE MARROW; RESPIRATORY; INTEGUEMENT Page 1 Prelab #4 BLOOD; BONE MARROW; RESPIRATORY; INTEGUEMENT Page 1 Blood Slide 101 This a classic slide of blood cells using a Wright stain. Inspect red blood cells and their appearance. Note the approximate

More information

The Growing Epidemic of Diabetes

The Growing Epidemic of Diabetes The Ad Hoc Group for Medical Research Luncheon Briefing for Senate and House Staff The Growing Epidemic of Diabetes and What the NIH Is Doing About It Griffin. Rodgers, M.D., M.A.C.. Director National

More information

AMR in Liver Transplantation: Incidence

AMR in Liver Transplantation: Incidence AMR in Liver Transplantation: Incidence Primary AMR 1/3 to 1/2 of ABO-incompatible transplants Uncommon with ABO-compatible transplant Secondary AMR Unknown incidence: rarely tested Why is AMR uncommon

More information

UC SF. Liver and Gastrointestinal Pathology Update. University of California San Francisco. September 3, 2009

UC SF. Liver and Gastrointestinal Pathology Update. University of California San Francisco. September 3, 2009 Liver and Gastrointestinal Pathology Update UC SF University of California San Francisco Nonalcoholic Fatty Liver Disease Update in Pathology September 3, 2009 Elizabeth M. Brunt, MD Department of Pathology

More information

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging for further reference: Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach Neil Theise, MD. Depts of Pathology

More information

Liver and gall bladder curriculum for ST1, presented at Northern block teaching, January 2017.

Liver and gall bladder curriculum for ST1, presented at Northern block teaching, January 2017. Liver and gall bladder curriculum for ST1, presented at Northern block teaching, January 2017. 1 The 2015 RCPath Stage A curriculum for hepatobiliary pathology and gall bladder. 2 The stage A curriculum

More information

Hormonal regulation of. Physiology Department Medical School, University of Sumatera Utara

Hormonal regulation of. Physiology Department Medical School, University of Sumatera Utara Hormonal regulation of nutrient metabolism Physiology Department Medical School, University of Sumatera Utara Homeostasis & Controls Successful compensation Homeostasis reestablished Failure to compensate

More information

Autoimmune Hepatitis: Histopathology

Autoimmune Hepatitis: Histopathology REVIEW Autoimmune Hepatitis: Histopathology Stephen A. Geller M.D.*, Autoimmune hepatitis (AIH), a chronic hepatic necroinflammatory disorder, occurs mostly in women. AIH is characterized by prominent

More information

NAFLD & NASH: Russian perspective

NAFLD & NASH: Russian perspective NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received

More information

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA UNIGASTRO Il fegato come centrale metabolica e i fattori di danno oltre ai virus epatitici IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA Dr Elisabetta Bugianesi Divisione di Gastro-Epatologia

More information

Understanding your FibroScan Results

Understanding your FibroScan Results PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

CHAPTER 1. Alcoholic Liver Disease

CHAPTER 1. Alcoholic Liver Disease CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end

More information

Occlusive Venous Lesions in Alcoholic Liver Disease

Occlusive Venous Lesions in Alcoholic Liver Disease GASTROENTEROLOGY 1982;83:786-96 Occlusive Venous Lesions in Alcoholic Liver Disease A Study of 200 Cases ZACHARY D. GOODMAN and KAMAL G. ISHAK From the Department of Hepatic Pathology, Armed Forces Institute

More information

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to

More information

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding

More information

Metabolic defects underlying dyslipidemia in abdominal obesity

Metabolic defects underlying dyslipidemia in abdominal obesity Metabolic defects underlying dyslipidemia in abdominal obesity Professor Marja-Riitta Taskinen Department of Medicine, Division of Cardiology Helsinki University Hospital, Finland Disclosures: Honorariums/

More information

AASLD: Boston Rob Goldin

AASLD: Boston Rob Goldin AASLD: Boston 2014 Rob Goldin r.goldin@imperial.ac.uk Autoimmune hepatitis 31 Does genuine acute autoimmune hepatitis have a better prognosis? 32 Patients with Autoimmune Hepatitis and Advanced Disease

More information

MICROSCOPIC STRUCTURE OF LIVER, GALLBLADDER, GALL DUCTS, AND PANCREAS OVERVIEW OF DEVELOPMENT OF THE ALIMENTARY CANAL

MICROSCOPIC STRUCTURE OF LIVER, GALLBLADDER, GALL DUCTS, AND PANCREAS OVERVIEW OF DEVELOPMENT OF THE ALIMENTARY CANAL Lecture 2 ESS_3rd semester MICROSCOPIC STRUCTURE OF LIVER, GALLBLADDER, GALL DUCTS, AND PANCREAS OVERVIEW OF DEVELOPMENT OF THE ALIMENTARY CANAL MICROSCOPIC STRUCTURE OF LIVER - is the largest gland of

More information

[Sem Liver Disease 21(1):81-88, Thieme Medical Publishers, Inc.]

[Sem Liver Disease 21(1):81-88, Thieme Medical Publishers, Inc.] Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies [Sem Liver Disease 21(1):81-88, 2001. 2001 Thieme Medical Publishers, Inc.] Paul Angulo, M.D., and Keith D. Lindor, M.D., Division

More information

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based

More information

Targeting Inflammation in Breast Cancer Pathogenesis

Targeting Inflammation in Breast Cancer Pathogenesis Targeting Inflammation in Breast Cancer Pathogenesis Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service Attending Physician, MSKCC Professor of Medicine, Weill Cornell Medical College August 7,

More information

LIVER DISEASES. Pathology Department, Zhejiang University School of Medicine,

LIVER DISEASES. Pathology Department, Zhejiang University School of Medicine, LIVER DISEASES Pathology Department, Zhejiang University School of Medicine, 马丽琴,maliqin198@zju.edu.cn Viral Hepatitis Cirrhosis of liver Liver cancer Viral Hepatitis DEFINITION Primary hepatic infections

More information

Non-Cirrhotic Portal Hypertension and Incomplete Septal Cirrhosis. Stefan Hübscher, University of Birmingham, Birmingham B15 2TT, U.K.

Non-Cirrhotic Portal Hypertension and Incomplete Septal Cirrhosis. Stefan Hübscher, University of Birmingham, Birmingham B15 2TT, U.K. Non-Cirrhotic Portal Hypertension and Incomplete Septal Cirrhosis Stefan Hübscher, University of Birmingham, Birmingham B15 2TT, U.K. Non-Cirrhotic Portal Hypertension Problems with Liver Biopsy Diagnosis

More information

Interesting Cases from Liver Tumor Board. Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine

Interesting Cases from Liver Tumor Board. Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine Interesting Cases from Liver Tumor Board Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine jeffrey.weinreb@yale.edu Common Liver Diseases Hemangioma Cyst FNH Focal Fat/Sparing THID Non-Cirrhotic

More information

METABOLISM of ADIPOSE TISSUE

METABOLISM of ADIPOSE TISSUE METABOLISM of ADIPOSE TISSUE 2. LF UK Prof. Rudolf Poledne, PhD. TYPES OF ADIPOSE TISSUE brown adipose tissue subcutaneous adipose tissue visceral adipose tissue ADIPOSE TISSUE FUNCTIONS: thermal isolation

More information

Original Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION

Original Article. Significance of Hepatic Steatosis in Chronic Hepatitis B Infection INTRODUCTION Original Article Bhanthumkomol P, et al. THAI J GASTROENTEROL 2013 Vol. 14 No. 1 Jan. - Apr. 2013 29 Bhanthumkomol P 1 Charatcharoenwitthaya P 1 Pongpaiboon A 2 ABSTRACT Background: Significance of liver

More information

Dr.Kamal Waheeb AlGhalayini MD, SCC Med. MSc-Card Associate professor, Consultant Cardiology. Head non-invasive lab. Vice dean for clinical affaires

Dr.Kamal Waheeb AlGhalayini MD, SCC Med. MSc-Card Associate professor, Consultant Cardiology. Head non-invasive lab. Vice dean for clinical affaires Dr.Kamal Waheeb AlGhalayini MD, SCC Med. MSc-Card Associate professor, Consultant Cardiology. Head non-invasive lab. Vice dean for clinical affaires King Abdulaziz University. Doc, I am fat because my

More information

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-

More information

Bacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative

Bacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative Patient: SAMPLE PATIENT DOB: Sex: MRN: 3.2 0.9-26.8 U/g 1.2 0.2-3.3 mg/g 2.2 1.3-8.6 micromol/g 1.1 1.3-23.7 mg/g 1.1 0.2-3.5 mg/g Rare 1.0 0.2-8.8 mg/g Rare 4.4 2.6-32.4 mg/g 64.6 >= 13.6 micromol/g Bacteriology

More information

2014 CURRENT ISSUES IN PATHOLOGY

2014 CURRENT ISSUES IN PATHOLOGY 2014 CURRENT ISSUES IN PATHOLOGY SPECIAL STAINS IN LIVER BIOPSY PATHOLOGY Sanjay Kakar, MD University of California, San Francisco Trichrome stain : (1) Assess degree of fibrosis. H&E stain is not reliable

More information

-sheet 3. -Waseem Alhaj. Maha Shomaf

-sheet 3. -Waseem Alhaj. Maha Shomaf -sheet 3 -Basheer egbaria -Waseem Alhaj Maha Shomaf 1 P a g e Viral hepatitis have many types each type is associated with different outcomes complication, some can result in acute one,others result in

More information

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock. Extrahepatic Biliary Obstruction Stones Tumors Ductal Diseases: Ductal Diseases: Primary Biliary Primary Biliary Cirrhosis Cirrhosis Sclerosing Cholangitis Sclerosing Cholangitis Acute Injury: Viral Hepatitis

More information

The health risks associated with obesity are widespread and

The health risks associated with obesity are widespread and GASTROENTEROLOGY 2012;142:711 725 IN BASIC CLINICAL GASTROENTEROLOGY HEPATOLOGY Robert F. Schwabe and John W. Wiley, Section Editors Role of Obesity and Lipotoxicity in the Development of Nonalcoholic

More information

Page 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity

Page 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity Metabolic Update Patients selection and choice of procedure Professor John B Dixon MBBS, FRACGP, FRCP Edin, PhD NHMRC Senior Research Fellow Head of Clinical Obesity Research, Baker IDI Heart and Diabetes

More information

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic

More information

University of Warwick institutional repository:

University of Warwick institutional repository: University of Warwick institutional repository: http://go.warwick.ac.uk/wrap This paper is made available online in accordance with publisher policies. Please scroll down to view the document itself. Please

More information

Liver Fat Quantification

Liver Fat Quantification Liver Fat Quantification Jie Deng, PhD, DABMP Department of Medical Imaging May 18 th, 2017 Disclosure Research agreement with Siemens Medical Solutions 2 Background Non-alcoholic fatty liver diseases

More information

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics

More information

HOW TO DEFINE GOOD BIOMARKERS OF HEALTH? Suzan Wopereis

HOW TO DEFINE GOOD BIOMARKERS OF HEALTH? Suzan Wopereis HOW TO DEFINE GOOD BIOMARKERS OF HEALTH? Suzan Wopereis My personal objective: identification of biomarkers of (optimal) health Biomarker Definition: a characteristic that is objectively measured and evaluated

More information